Literature DB >> 28299382

[Immunological mechanisms of allergen-specific immunotherapy].

J-P Allam1, N Novak2.   

Abstract

Allergen-specific immunotherapy is accompanied by multiple changes on the cellular and humoral level. A shift of Th2 immune responses towards immune responses of the Th1 type, which goes along with an increase of regulatory T cells and B cells, IL-10 as well as reduction of effector cells and eosinophils in the tissue, combined with lower IgE production in favor of higher IgG4 production, are regarded as key mechanisms of allergen-specific immunotherapy . A better understanding of immunologic pathways of specific immunotherapy would be essential for the improvement of this therapy as well as for the development of reliable biomarkers capable to monitor therapeutic responses as well as compliance of the patients.

Entities:  

Keywords:  Biomarker; Compliance; Immune response; Tolerance; Type I allergy

Mesh:

Substances:

Year:  2017        PMID: 28299382     DOI: 10.1007/s00105-017-3961-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  25 in total

Review 1.  Noninjection routes for immunotherapy.

Authors:  Giorgio Walter Canonica; Giovanni Passalacqua
Journal:  J Allergy Clin Immunol       Date:  2003-03       Impact factor: 10.793

2.  Allergen-specific immunotherapy with recombinant grass pollen allergens.

Authors:  Marek Jutel; Lothar Jaeger; Roland Suck; Hanns Meyer; Helmut Fiebig; Oliver Cromwell
Journal:  J Allergy Clin Immunol       Date:  2005-09       Impact factor: 10.793

3.  Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity.

Authors:  Jürgen Reisinger; Friedrich Horak; Gabrielle Pauli; Marianne van Hage; Oliver Cromwell; Franz König; Rudolf Valenta; Verena Niederberger
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

Review 4.  Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report.

Authors:  M A Calderón; T Casale; L Cox; C A Akdis; A W Burks; H S Nelson; M Jutel; P Demoly
Journal:  Allergy       Date:  2013-07       Impact factor: 13.146

5.  100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT).

Authors:  Johannes Ring; J Gutermuth
Journal:  Allergy       Date:  2011-02-15       Impact factor: 13.146

6.  Initial immunological changes as predictors for house dust mite immunotherapy response.

Authors:  E Gómez; T D Fernández; I Doña; C Rondon; P Campo; F Gomez; M Salas; M Gonzalez; J R Perkins; F Palomares; M Blanca; M J Torres; C Mayorga
Journal:  Clin Exp Allergy       Date:  2015-10       Impact factor: 5.018

7.  Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy.

Authors:  Johannes Martin Schmid; Peter Adler Würtzen; Ronald Dahl; Hans Jürgen Hoffmann
Journal:  J Allergy Clin Immunol       Date:  2014-06-13       Impact factor: 10.793

8.  Early markers for protective mechanisms during rush venom immunotherapy.

Authors:  C Bussmann; J Xia; J-P Allam; L Maintz; T Bieber; N Novak
Journal:  Allergy       Date:  2010-12       Impact factor: 13.146

Review 9.  Immunoglobulin G4: an odd antibody.

Authors:  R C Aalberse; S O Stapel; J Schuurman; T Rispens
Journal:  Clin Exp Allergy       Date:  2009-02-13       Impact factor: 5.018

Review 10.  Mechanisms and treatment of allergic disease in the big picture of regulatory T cells.

Authors:  Cezmi A Akdis; Mübeccel Akdis
Journal:  J Allergy Clin Immunol       Date:  2009-04       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.